This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Market And Product Forecasts: Melanoma - Yervoy Will Continue To Dominate As New Approvals Struggle To Compete

MARKET DEFINITION •Market definition for melanoma

•Forecast methodology and assumptions - Methodology flow

- Patent expiries

- New product launches

•Additional forecast methodology

MARKET

OVERVIEW

AND CONTEXT•Melanoma therapies included in this report

•Current and future market dynamics overview - The branded melanoma market will experience a dramatic increase in sales over the forecast period

- Market entry of new drugs will dramatically increase the value of the branded melanoma market

- The commercial value of pipeline therapies will not surpass the total value of current marketed therapies

- New product launches will mostly impact the metastatic melanoma setting

- The US will remain the most lucrative market over the forecast period

- The overall value of branded melanoma therapies will increase across the five major EU markets

PRODUCT FORECASTS•Molecule dynamics - Yervoy will continue to dominate the melanoma market over the forecast period

•Yervoy (ipilimumab; Bristol-Myers Squibb) - Forecast assumptions

- Yervoy forecast 2012–21

•Zelboraf (vemurafenib; Roche/Daiichi Sankyo) - Forecast assumptions - Zelboraf forecast 2012–21

•Abraxane (albumin-bound paclitaxel; Celgene) - Forecast assumptions

- Abraxane forecast 2012–21

•Allovectin-7 (velimogene aliplasmid; Vical) - Forecast assumptions - Allovectin-7 forecast 2012–21

•Dabrafenib (GSK-2118436; GlaxoSmithKline) - Forecast assumptions

- Dabrafenib forecast 2012–21

•MAGE-A3 ASCI (astuprotimut-r; GlaxoSmithKline) - Forecast assumptions - MAGE-A3 ASCI forecast 2012–21

•OncoVEX GM-CSF (talimogene laherparepvec; Amgen) - Forecast assumptions

- OncoVEX forecast 2012–21

•POL-103A (Polynoma/CK Life Sciences) - Forecast assumptions - POL-103A forecast 2012–21

•Trametinib (GSK-1120212; GlaxoSmithKline) - Forecast assumptions

- Trametinib forecast 2012–21 BIBLIOGRAPHY

•Journal papers•Websites APPENDIX

•Forecast methodology - Volume and value forecast methodology- Price and compliance assumptions TABLES

•Table: Summary of therapeutic classes in melanoma by ATC code, 2012•Table: Patent expiry dates for key marketed brands in melanoma, 2012•Table: Estimated launch dates for key late-stage pipeline products in melanoma, 2012–21•Table: Drugs included in melanoma market and product forecasts, 2012–21•Table: Melanoma drug sales in the US and five major EU markets ($m), 2012–21•Table: Melanoma drug sales in the US ($m), 2012–21•Table: Melanoma molecule sales in the five major EU markets ($m), 2012–21•Table: Key melanoma drug sales in the US and five major EU markets, 2012 and 2021•Table: Yervoy sales, by country ($m), 2012–21•Table: Yervoy patients, by country, 2012–21•Table: Zelboraf sales, by country ($m), 2012–21•Table: Zelboraf patients, by country, 2012–21•Table: Abraxane sales, by country ($m), 2012–21•Table: Abraxane patients, by country, 2012–21•Table: Allovectin-7 sales, by country ($m), 2012–21•Table: Allovectin-7 patients, by country, 2012–21•Table: Dabrafenib sales, by country ($m), 2012–21•Table: Dabrafenib patients, by country, 2012–21•Table: MAGE-A3 ASCI sales, by country ($m), 2012–21•Table: MAGE-A3 ASCI patients, by country, 2012–21•Table: OncoVEX GM-CSF sales, by country ($m), 2012–21•Table: OncoVEX GM-CSF patients, by country, 2012–21•Table: POL-103A sales, by country ($m), 2012–21•Table: POL-103A patients, by country, 2012–21•Table: Trametinib sales, by country ($m), 2012–21•Table: Trametinib patients, by country, 2012–21•Table: Price sources and calculations, by country, 2012•Table: Exchange rates used for calculating prices, 2012 FIGURES

•Figure: Patient-based forecast methodology for melanoma, 2012•Figure: Melanoma market forecast across the US and five major EU markets, by country ($m), 2012–21•Figure: Melanoma sales in the US and five major EU markets, by class ($m), 2012–21•Figure: Estimated approval/launch dates of key melanoma therapies, 2012–21•Figure: Branded melanoma market value in the US, by drug class ($m), 2012–21•Figure: Branded melanoma market value in the five major EU markets, by drug class ($m), 2012–21•Figure: Key branded melanoma drug sales, 2012–21•Figure: Yervoy sales, by country ($m), 2012–21•Figure: Zelboraf sales, by country ($m), 2012–21•Figure: Abraxane sales, by country ($m), 2012–21•Figure: Allovectin-7 sales, by country ($m), 2012–21•Figure: Dabrafenib sales, by country ($m), 2012–21•Figure: MAGE-A3 ASCI sales, by country ($m), 2012–21•Figure: OncoVEX GM-CSF sales, by country ($m), 2012–21•Figure: POL-103A sales, by country ($m), 2012–21•Figure: Trametinib sales, by country ($m), 2012–21

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs